查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1420995

流感藥物市場（產品：扎那米韋、奧司他韋、帕拉米韋、金剛烷胺、金剛乙胺、肌苷等）- 全球產業分析、規模、佔有率、成長、趨勢和預測，2023- 2031 年

Influenza Medication Market (Product: Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 159 Pages | 商品交期: 2-10個工作天內

價格

流感藥物市場 - 報告範圍

TMR 關於全球流感藥物市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球流感藥物市場的收入2017-2031年期間，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球流感藥物市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解流感藥物市場。

市場概況
2023年市場價值 9.07 億美元
2031 年市場價值 11 億美元
CAGR 2.2%

該報告深入研究了全球流感藥物市場的競爭格局。全球流感藥物市場的主要參與者已被確定，並且每個參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球流感藥物市場參與者的屬性。

目錄

第 1 章：執行摘要

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 市場區隔
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • COVID-19 大流行對該行業的影響

第 6 章：市場分析與預測：依產品類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依產品類型，2017-2031
    • 扎那米韋
    • 奧司他韋
    • 帕拉米韋
    • 金剛烷胺
    • 金剛乙胺
    • 肌苷
    • 其他（辛酸拉尼米韋等）
  • 市場吸引力：按產品類型

第 7 章：全球市場分析與預測：按配銷通路

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2023-2031
    • 醫院
    • 診所
    • 藥局
    • 其他
  • 市場吸引力：按配銷通路

第 8 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 9 章：北美市場分析與預測

第 10 章：歐洲市場分析與預測

第 11 章：亞太市場分析與預測

第 12 章：拉丁美洲市場分析與預測

第 13 章：中東和非洲市場分析與預測

第 14 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.,
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Sun Pharmaceutical Industries Ltd.
    • Mylan, Inc.
    • GlaxoSmithKline plc
    • Daiichi Sankyo Company
    • Natco Pharma
Product Code: TMRGL24038

Influenza Medication Market - Scope of Report

TMR's report on the global influenza medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global influenza medication market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global influenza medication market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the influenza medication market.

Market Snapshot
Market Value in 2023US$ 907 Mn
Market Value in 2031US$ 1.1 Bn
CAGR2.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global influenza medication market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global influenza medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global influenza medication market.

The report delves into the competitive landscape of the global influenza medication market. Key players operating in the global influenza medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global influenza medication market profiled in this report.

Key Questions Answered in Global influenza medication Market Report:

  • What is the sales/revenue generated by influenza medication across all regions during the forecast period?
  • What are the opportunities in the global influenza medication market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Influenza Medication Market - Research Objectives and Research Approach

The comprehensive report on the global influenza medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global influenza medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global influenza medication market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Influenza Medication Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Influenza Medication Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. COVID-19 Pandemic Impact on Industry

6. Influenza Medication Market Analysis and Forecast, by Product Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2017-2031
    • 6.3.1. Zanamivir
    • 6.3.2. Oseltamivir
    • 6.3.3. Peramivir
    • 6.3.4. Amantadine
    • 6.3.5. Rimantadine
    • 6.3.6. Inosine
    • 6.3.7. Others (Laninamivir Octanoate, etc.)
  • 6.4. Market Attractiveness, by Product Type

7. Global Influenza Medication Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Pharmacies
    • 7.3.4. Others
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Influenza Medication Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Influenza Medication Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Product Type, 2017-2031
    • 9.2.1. Zanamivir
    • 9.2.2. Oseltamivir
    • 9.2.3. Peramivir
    • 9.2.4. Amantadine
    • 9.2.5. Rimantadine
    • 9.2.6. Inosine
    • 9.2.7. Others (Laninamivir Octanoate, etc.)
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Pharmacies
    • 9.3.4. Others
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Product Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Influenza Medication Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product Type, 2017-2031
    • 10.2.1. Zanamivir
    • 10.2.2. Oseltamivir
    • 10.2.3. Peramivir
    • 10.2.4. Amantadine
    • 10.2.5. Rimantadine
    • 10.2.6. Inosine
    • 10.2.7. Others (Laninamivir Octanoate, etc.)
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospitals
    • 10.3.2. Clinics
    • 10.3.3. Pharmacies
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Product Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Influenza Medication Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product Type, 2017-2031
    • 11.2.1. Zanamivir
    • 11.2.2. Oseltamivir
    • 11.2.3. Peramivir
    • 11.2.4. Amantadine
    • 11.2.5. Rimantadine
    • 11.2.6. Inosine
    • 11.2.7. Others (Laninamivir Octanoate, etc.)
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospitals
    • 11.3.2. Clinics
    • 11.3.3. Pharmacies
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Product Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Influenza Medication Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product Type, 2017-2031
    • 12.2.1. Zanamivir
    • 12.2.2. Oseltamivir
    • 12.2.3. Peramivir
    • 12.2.4. Amantadine
    • 12.2.5. Rimantadine
    • 12.2.6. Inosine
    • 12.2.7. Others (Laninamivir Octanoate, etc.)
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospitals
    • 12.3.2. Clinics
    • 12.3.3. Pharmacies
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Product Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Influenza Medication Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product Type, 2017-2031
    • 13.2.1. Zanamivir
    • 13.2.2. Oseltamivir
    • 13.2.3. Peramivir
    • 13.2.4. Amantadine
    • 13.2.5. Rimantadine
    • 13.2.6. Inosine
    • 13.2.7. Others (Laninamivir Octanoate, etc.)
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospitals
    • 13.3.2. Clinics
    • 13.3.3. Pharmacies
    • 13.3.4. Others
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Product Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. F. Hoffmann-La Roche Ltd.,
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Teva Pharmaceutical Industries Ltd.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Sandoz International GmbH
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Sun Pharmaceutical Industries Ltd.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Mylan, Inc.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. GlaxoSmithKline plc
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Daiichi Sankyo Company
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Natco Pharma
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview

List of Tables

  • Table 01: Global Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 02: Global Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Influenza Medication Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 05: North America Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: North America Influenza Medication Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 08: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 11: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 14: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 17: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 02: Global Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 03: Global Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 04: Global Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 05: Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 06: Global Influenza Medication Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Influenza Medication Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 08: North America Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 09: North America Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 10: North America Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 11: North America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 12: North America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 13: North America Influenza Medication Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Influenza Medication Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 15: Europe Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 16: Europe Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 17: Europe Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 18: Europe Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 19: Europe Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 20: Europe Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 23: Asia Pacific Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 24: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 25: Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 26: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Asia Pacific Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Latin America Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 30: Latin America Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 31: Latin America Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 32: Latin America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Latin America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: Latin America Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 36: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 37: Middle East & Africa Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 38: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 39: Middle East & Africa Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 41: Middle East & Africa Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Global Influenza Medication Market Share Analysis, by Company, 2022